Stocktoria
Aspire Biopharma Holdings, Inc. ASBP
Aspire Biopharma Holdings, Inc. (ASBP) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $6,202 at a -394725.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ASBP | Aspire Biopharma Holdings, Inc. | 2/9 | — | — | — |
| TCRT | Alaunos Therapeutics, Inc. | 2/9 | — | — | — |
| GNLX | GENELUX Corp | 2/9 | — | — | — |
| ZNTL | Zentalis Pharmaceuticals, Inc. | 1/9 | -8.96 | — | -100% |
| XCUR | EXICURE, INC. | 1/9 | — | — | — |
| VTVT | vTv Therapeutics Inc. | 3/9 | -5.57 | — | — |
| VKTX | Viking Therapeutics, Inc. | 1/9 | 7.05 | — | — |
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, such as melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
FAQ
Is ASBP financially healthy?
Aspire Biopharma Holdings, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does ASBP pay a dividend?
No, Aspire Biopharma Holdings, Inc. does not currently pay a dividend.
How profitable is ASBP?
In FY2025, Aspire Biopharma Holdings, Inc. had a net margin of -394725.1%.
Is ASBP a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Aspire Biopharma Holdings, Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.